Already registered? Login below:

Login commences 30 minutes to start time.



Latest developments in ovarian cancer


When: Thursday, April 16, 2020
Time: 7:00pm - 8:00pm AEST
Where:
Online - join via your computer!
Your Host: Vanessa Alford
Your Presenters: Dr Yoland Antill, Prof Michael Friedlander and Kristin Young
Cost: Complimentary 


About the Webinar

This webinar will provide information about the latest developments in Ovarian cancer research, including some of the clinical trials that are currently underway and new therapies emerging for ovarian cancer.

In this webinar, we will hear from Professor Michael Friedlander, a conjoint Professor of Medicine at the University of NSW and a medical oncologist at the Prince of Wales Hospital and Royal Hospital for Women, who will talk about the use of PARP inhibitors in ovarian cancer.

Dr Yoland Antill, a medical oncologist and cancer genetics specialist based in Melbourne will focus on germline and somatic genetic testing in ovarian cancer.

We will also hear from Kristin Young, who was diagnosed with Stage IIIC Ovarian Cancer in September 2009 and has been on clinical trials for much of that time. Kristin will share her experience of being involved in clinical trials.



About the Presenters

Register Today!

Professor Michael Friedlander

Professor Michael Friedlander is conjoint Professor of Medicine at the University of NSW and a medical oncologist at the Prince of Wales Hospital and Royal Hospital for Women. Over the course of his career, he has had a leading role in gynecological cancer clinical trials nationally and internationally. He has held many leadership positions including inaugural chair of ANZGOG as well as President of the IGCS. He has been closely involved since 2007 in the early and later phase trials of PARP inhibitors in ovarian and breast cancer. Professor Friedlander has co-authored 400 publications and received numerous awards in recognition of his contribution to gynecological oncology. In this webinar Professor Friedlander will talk about the use of PARP inhibitors in ovarian cancer.

Dr Yoland Antill

Dr Yoland Antill is a Medical Oncologist and Cancer Genetics Specialist based in Melbourne with appointments at Frankston Hospital, Royal Melbourne Hospital and Cabrini Health. She holds an Adjunct Senior Research Fellow position with Monash University. Her work and research interests are in the management of Breast and Gynaecological cancers. Dr Antill is a member of the Medical Oncology Group of Australia, the Australian Gynaecological Oncology Group (Research Advisory Committee Member and Chair of the Uterine Tumour Working Group) and the American Society of Clinical Oncology. She has more than 15 years' experience in both medical oncology and in the diagnosis and management of hereditary cancer syndromes. Dr Yoland Antill will focus on germline and somatic genetic testing in ovarian cancer.


Kristin Young

Kristin was diagnosed with Stage IIIC Ovarian Cancer in September 2009 and has been on clinical trials for much of that time. She has proven to be a super responder on Olaparib and for her the success of this drug is testament to the value of conducting research into new treatments. Kristin hopes that raising awareness of clinical trials and research will lead to more women benefiting from new treatments the way she has. In this webinar Kristin will share her experience of being involved in clinical trials.




For technical assistance, please email Redback Support or call 1800 733 416.

Your personal information will be collected for the purpose of this webinar only. Please contact the organisation hosting this event should you require details on your privacy rights.